日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting vascular adhesion protein-1 and myeloperoxidase with a dual inhibitor SNT-8370 in preclinical models of inflammatory disease.

在炎症疾病的临床前模型中,使用双重抑制剂 SNT-8370 靶向血管粘附蛋白-1 和髓过氧化物酶

Glaros Elias, Foot Jonathan, Rayner Ben, Schilter Heidi, Zhang Yunjia, Paumann-Page Martina, Teixeira Mauro M, Jarolimek Wolfgang, Thomas Shane R

The small molecule LOXL2 inhibitor SNT-5382 reduces cardiac fibrosis and achieves strong clinical target engagement.

小分子 LOXL2 抑制剂 SNT-5382 可减少心脏纤维化,并实现强大的临床靶点结合

Perryman Lara, Findlay Alison, Baskar Jana, Charlton Brett, Foot Jonathan, Hamilton Ross, Hamprecht Dieter, Joshi Amar, Stolp Jessica, Turner Craig, Zahoor Amna, Zhou Wenbin, López Begoña, Ravassa Susana, González Arantxa, Jarolimek Wolfgang

An activity-based bioprobe differentiates a novel small molecule inhibitor from a LOXL2 antibody and provides renewed promise for anti-fibrotic therapeutic strategies

一种基于活性的生物探针能够区分新型小分子抑制剂和LOXL2抗体,并为抗纤维化治疗策略带来新的希望。

Findlay, Alison; Turner, Craig; Schilter, Heidi; Deodhar, Mandar; Zhou, Wenbin; Perryman, Lara; Foot, Jonathan; Zahoor, Amna; Yao, Yimin; Hamilton, Ross; Brock, Mary; Raso, Christina; Stolp, Jessica; Galati, Marie; Hamprecht, Dieter; Charlton, Brett; Jarolimek, Wolfgang